ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

shamrock Evaluation of clinicopathological profiles and development of a risk model in renal epithelioid angiomyolipoma patients: a large-scale retrospective cohort study

Anwaier, Aihetaimujiang; Xu, Wen-Hao; Tian, Xi; Ding, Tao; Su, Jia-Qi; Wang, Yue; Qu, Yuan-Yuan*; Zhang, Hai-Liang*; Ye, Ding-Wei*复旦大学; 南方医科大学
BMC Urology2022-9-12DOI: 10.1186/s12894-022-01101-9
5阅读
引用收藏
分享

摘要

Background To identify the malignant potential and prognostic indicators of renal epithelioid angiomyolipoma (eAML), clinicopathological and molecular features as well as the drug efficacy of 67 eAML cases were analyzed. Materials and methods Sixty-seven renal eAML patients were enrolled and the immunohistochemical features of these patients were examined. FFPE slides of all patients were re-examined. 21 patients with metastasis received Everolimus 10 mg orally once daily. Responses were evaluated with RECIST criteria by three authors. A risk stratification model was constructed using the following factors: pT3 and pT4, presence of necrosis, mitotic count >= 2; the presence of atypical mitoses; severe nuclear atypia, SMA negative, Ki-67 >= 10%. Results The average percentage of the epithelioid component was 85.6% (range 80-95%). Immunohistochemically, Ki-67 >= 10% and negative SMA staining were significantly correlated with malignant characteristics (Ki-67: p < 0.001; SMA: p = 0.001). Survival analysis suggested that pT3-pT4 stage, presence of necrosis, severe nuclear atypia, presence of atypical mitoses, mitotic count >= 2, Ki-67 >= 10% and negative SMA expression were significantly associated with poorer PFS and OS (p < 0.05). The risk model sufficiently discriminated recurrence/metastasis (AUC = 0.897) and cancer-specific mortality (AUC = 0.932) of renal eAML patients in different risk groups. 21 patients had received Everolimus targeted therapy after recurrence/metastasis. The best response for Everolimus treatment was 8/21 (38.1%) partial responses (PR), 9/21 (42.9%) stable disease (SD) and 4/21 (19.0%) progressive disease (PD). Conclusion The risk stratification model could well distinguish eAML patients at high risk of recurrence/metastasis. Everolimus targeted treatment showed good efficacy in patients with recurrence/metastasis.

学科与关键词

关键词
Renal epithelioid angiomyolipomaSMAKi-67BiomarkersPredictive model
相关
加载中…
  • Renal epithelioid angiomyolipoma: computed tomography manifestation and radiologic-pathologic correlation depending on different epithelioid component percentages
    Luo, Chun*; Liu, Ziwei*; Gao, Mingyong; Hu, Qiugen; He, Xiaohong; Xi, Yue; Cai, Fengqin; Zhang, Rong; Zeng, Xiaofeng; Xiao, NiAbdominal Radiology, 2022, 47(1): 310-319.被引 4
  • Malignant epithelioid angiomyolipoma of the kidney with pulmonary metastases and p53 gene mutation
    Jun, Li; Ming, Zhu; Yan-Li, WangWorld Journal of Surgical Oncology, 2012, 10(1): 213.被引 10
  • A Clinical Challenge Case of Bilateral Giant Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex
    Tang, Guixing; Li, Zhiyong; Zhang, Zhiling; Luo, Cheng; Dong, Pei*Urology, 2022, 169: E11-E12.
查看全部 →

发表信息

论文状态
公开发表
期刊
BMC Urology
发表日期
2022-09-12
卷期
第 22 卷, 第 1 期
页码
148
DOI
10.1186/s12894-022-01101-9
语言
ENGLISH
期刊等级
4区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81772706, 81802525, 821172817]; National Key Research and Development Program of China Project [2019YFC1316005]

作者

  • A

    Anwaier, Aihetaimujiang (第一作者)

    fudan univ

  • X

    Xu, Wen-Hao

    fudan univ

查看全部 9 位作者收起作者
  • T

    Tian, Xi

    fudan univ

  • D

    Ding, Tao

    southern med univ

  • S

    Su, Jia-Qi

    fudan univ

  • W

    Wang, Yue

    fudan univ

  • Q

    Qu, Yuan-Yuan (通讯)

    fudan univ

  • Z

    Zhang, Hai-Liang (通讯)

    fudan univ

  • Y

    Ye, Ding-Wei (通讯)

    fudan univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417